Information about relative biomarker timing and the consistency of this timing will likely be important to inform diagnostic testing for Alzheimer’s disease pathology in preclinical Alzheimer’s disease as trials and treatment progress towards secondary prevention and as anti-tau and other therapies are developed. This evidence concerns the gene MAPT and Alzheimer disease.